New Interview with CEO of BriaCell Therapeutics Corp.

President and CE Oof BriaCell Therapeutics Corp. Discusses positive breast cancer efficacy data with Bria-IMT Immunotherapy Treatment in new interview with Small CapVoice Inc. (“SCV”) announces the availability of a new interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT), to discuss three key achievements that support the Company’s continued growth. The Company recently announced positive initial efficacy data in its 2021-2022 cohort of 12 advanced breast cancer patients. Disease control, tumor shrinkage, and potential survival benefit were observed amongst 12 patients in the Phase I/IIa clinical study of Bria-IMT™ in combination with Incyte’s retifanlimab.
Bria-IMT™ regimen in combination with Incyte’s retifanlimab produced evidence of disease control, tumor shrinkage, and potential survival benefit amongst BriaCell’s recent 12 patient cohort in advanced breast cancer. The study, recently awarded U.S. Food and Drug Administration (“FDA”) fast track designation, continues with additional clinical data forthcoming.

The regimen remains well tolerated as recently reported in Phase I evaluation.

70% of patients showed either disease control or progression-free survival (PFS) benefits compared with their last therapy.

Prior to enrollment, the 12 patients in the cohort had already been unsuccessfully heavily pre-treated with at least 2 prior therapy regimens, further underscoring BriaCell’s positive patient outcomes.

Link to full disclosure about compensation paid to by companies featured on our website or in our e-mail communications.